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Background: A considerable proportion of autoimmune hemolytic anemia (AIHA) are secondary to underlying
autoimmune disorders, especially syetemic lupus erythematosus (SLE), and the clinical and laboratory index for early
discrimination between primary and SLE-related AIHA has yet to be defined. In the present study, we proposed
novel cytokine patterns in the pathogenesis of AIHA as well as parameters for the timely identification of
SLE-related patients.
Methods: AIHA patients confirmed by immunohematology techniques from September 2010 to December 2012
in our facility were consecutively included and categorized into primary (n = 19) and SLE-related (n = 18) groups.
Plasma cytokine profiles were measured in a single procedure by Quantibody Human Inflammatory Array 1
(RayBiotech, Norcross, GA).
Results: SLE-related AIHA patients demonstrated younger age (39 ± 20 vs.57 ± 16 years, p = 0.004), poorer
reticulocyte compensation (6.8 ± 7.1 vs.12.2 ± 8.6%, p = 0.045), lower levels of lactate dehydrogenase [361 (265-498)
vs. 622 (387-1154) U/L, p = 0.004], and higher occurrence of anticardiolipin antibody [9/18 (50%) vs. 2/19 (10.9%),
p = 0.009]. MCP-1/CCL2, MIP-1β/CCL4, BLC/CXCL13, IL-8/CXCL8, sTNFRI, and sTNFRII were significantly up-regulated
in both groups, while sTNFRII was remarkably higher in SLE-related patients. Among both groups, hemoglobin level
was negatively correlated with CXCL13 (r = -0.332, p = 0.044), while reticulocyte count was positively correlated with
CCL4 (r = 0.456, p = 0.005).
Conclusion: CXCL13 and CCL4 could act as circulating biomarkers in AIHA, and indicated disease severity and erythroid
compensation, respectively. Higher plasma sTNFRII might favor the diagnosis of SLE-related instead of primary AIHA.
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Autoimmune hemolytic anemia (AIHA), classified into
warm AIHA and cold agglutinin syndrome, are character-
ized by robust erythrocyte autoantibody production to vari-
ous extents. As high as 50% of warm AIHA and 90% of
cold agglutinin syndrome are considered to be secondary
to infections, malignancies, and systemic autoimmune dis-
orders including systemic lupus erythematosus (SLE), thus
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unless otherwise stated.AIHA [1-3]. The autoantibody-centered concept for the
pathogenesis of AIHA has been complemented, if not en-
tirely altered by accumulating understandings of T helper
cell and its functional subgroups. Previous studies revealed
elevation of IL-10 production in both peripheral blood and
spleen Th population, and suggested potential role of Treg
and Th1 cells in AIHA [4-6]. However, the exact dominat-
ing Th functional population is yet to be identified in
AIHA, which allows us to look for additional circulating
cytokine markers that might have played potential roles in
the pathogenesis of AIHA. The present study utilized a
multiplex detection system to illustrate plasma cytokine
portraits in primary and SLE-related AIHA patients, thusis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in this highly heterogeneous disease group.
Materials and methods
Study population
AIHA patients confirmed by immunohematology tech-
niques including direct antiglobulin test and gel microcol-
umn antiglobulin assay from September 2010 to December
2012 in our facility were consecutively included. Patient
history and baseline laboratory parameters were collected
by a hematologist at the time of diagnosis. Additional panel
of autoantibodies including anti-nuclear antibody, anti-
cardiolipin antibody, and extractable nuclear antibodies
were performed in all patients, and the diagnosis of SLE
was made according to the American College of Rheuma-
tology criteria [7]. When overt lymphadenopathy was
present and lymphoid malignancies suspected, lymphade-
nectomy biopsy was performed to confirm or exclude the
diagnosis. The health control group comprised of 10
healthy adults (6 males and 4 females) at median age of 34
(24-46) years without known history of malignancies, auto-
immune diseases, or recent infections. The study was ap-
proved by Medical Ethics Committee of Zhongshan
Hospital of Fudan University. Written informed consent
was obtained from each patient before being included in
the study.
Plasma inflammation cytokine array
Cytokine profiles were measured by Quantibody Human
Inflammatory Array 1 (RayBiotech, Norcross, GA) which
permitted detection of 40 inflammation-associated cyto-
kines including IFN-γ, I-309/CCL1, MCP-1/CCL2, MIP-
1α/CCL3, MIP-1β/CCL4, MIP-1δ/CCL15, RANTES/
CCL5, Eotaxin/CCL11, Eotaxin-2/CCL24, MIG/CXCL9,
BLC/CXCL13, G-CSF, M-CSF, GM-CSF, ICAM-1, IL-1α,
IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-6sR, IL-7, IL-8/
CXCL8, IL-10, IL-11, IL-12p40, IL-12p70, IL-13, IL-15,
IL-16, IL-17, TIMP-1, TIMP-2, PDGF-BB, TNFα, TNFβ,
sTNFRI and sTNFRII in a single procedure using plasma
samples cryopreserved at -80°C. The protein array slides
spotted by specific capture antibodies were incubated
with thawed plasma samples, washed, and incubated
with a cocktail of biotinylated antibodies using protocol
provided by the manufacturer. The slides with bound
biotin were then incubated with streptavidin-conjugated
Hylite Plus 555 fluor. Relative fluorescent strength was
detected by LuxScan 10 K-A Microarray Scanner (Capi-
talBio Corporation, Beijing, China). The actual protein
concentration was obtained on the standard curve plot-
ted via standard controls incorporated into the array.
Statistical analyses
Analysis was performed with the SPSS 11.5 software
(SPSS, Chicago, IL, USA). Data were reported as mean± standard deviation or medians (inter-quartile ranges)
for continuous variables and as frequencies (percentages)
for categorical variables. Continuous variables between
groups were assessed by the one-way ANOVA or Mann-
Whitney U-test as appropriate. Differences in percent-
ages were evaluated using the χ2 tests or Fisher’s exact
tests. The correlation between circulating cytokine levels
and clinical parameters was calculated by Pearson’s cor-
relation coefficient or Spearman rank correlation coeffi-
cient as appropriate. Statistical significance was defined
as two-sided P < 0.05. The level of significance for pair-
wise comparisons was adjusted when multiple compari-
sons were performed (p = 0.05 / 3 = 0.017).
Results and discussion
Clinical characteristics of primary and SLE-related AIHA
From September 2010 to December 2012, 46 patients
were serologically confirmed as warm antibody AIHA in
our facility, among which 18 patients were later catego-
rized as SLE-related AIHA, 7 lymphoma-related AIHA
(4 angioimmunoblastic T cell lymphomas, 2 chronic
lymphocytic leukemias, and 1 nodal marginal zone
lymphoma), 1 drug-induced AIHA, 1 related to non-
hematological malignancy, and the rest 19 patients were
categorized as primary AIHA.
SLE-related AIHA patients were significantly younger
than primary cases at the time of diagnosis (39 ± 20 vs.57
± 16 years, p = 0.004), meanwhile the serological parame-
ters for hemolysis including lactate dehydrogenase [361
(265-498) vs. 622 (387-1154) U/L, p = 0.004], total biliru-
bin (1.4 ± 1.4 vs.3.1 ± 1.7 mg/dl, p = 0.002), and conjugated
bilirubin (0.7 ± 0.7 vs.1.9 ± 1.3 mg/dl, p = 0.002) were less
prominently elevated. Gender distribution, severity of
anemia, and platelet count were similar between SLE-
related and primary AIHA patients, although reticulocyte
count seemed to be lower in SLE-related cases (6.8 ± 7.1
vs.12.2 ± 8.6%, p = 0.045). Except for anticardiolipin anti-
body [9/18 (50%) vs. 2/19 (10.9%), p = 0.009], major im-
munological parameters including complement levels,
anti-nuclear antibody, direct antiglobulin test, indirect an-
tiglobulin test, and peripheral lymphocyte phenotype were
all comparable between SLE-related and primary AIHA
patients (Table 1).
Plasma cytokine portraits of primary and SLE-related
AIHA
Within the detection panel of inflammation-associated
cytokines measured, MCP-1/CCL2, MIP-1β/CCL4, IL-8/
CXCL8, BLC/CXCL13, sTNFRI and sTNFRII were found
to be significantly up-regulated in both SLE-related and pri-
mary AIHA patients, while sTNFRII was remarkably higher
in SLE-related cases. On the other hand, established cyto-
kine markers for renowned Th functional subgroups such
as Th1 (IFN-γ), Th2 (IL-4), and Th17 (IL-17) were stable,
Table 1 Baseline characteristics of primary and SLE-related AIHA patients
Primary (n = 19) SLE-related (n = 18) p value
Age, years 57 ± 16 39 ± 20 0.004※
Female gender 9 (47.4) 13 (72.2) 0.124
Hemoglobin, g/dl 6.9 ± 1.9 7.9 ± 2.6 0.199
Reticulocyte count,% 12.2 ± 8.6 6.8 ± 7.1 0.045§
Platelet count, ×109/L 166 ± 104 171 ± 101 0.874
Total bilirubin, mg/dl 3.1 ± 1.7 1.4 ± 1.4 0.002※
Unconjugated bilirubin, mg/dl 1.9 ± 1.3 0.7 ± 0.7 0.002※
Lactate dehydrogenase, U/L 622 (387-1154) 361 (265-498) 0.004※
Complements
C3, mg/dl 73.6 ± 31.8 56.5 ± 36.7 0.296
C4, mg/dl 9.4 ± 5.5 7.2 ± 6.7 0.451
Direct antiglobulin test
Anti-IgG (+) 19 (100) 18 (100) 1.000
Anti-C3d (+) 15 (78.9) 17 (94.4) 0.370
Autoantibodies
Antinuclear antibody (+) 13 (68.4) 17 (94.4) 0.110
Anticardiolipin antibody (+) 2 (10.5) 9 (50.0) 0.009※
Indirect antiglobulin test, titer 8 (1-32) 2 (1-4) 0.169
Peripheral lymphocyte phenotype
CD3+CD4+,% 36 ± 20 34 ± 9 0.804
CD3+CD8+,% 33 ± 18 40 ± 11 0.294
CD16+CD56+,% 7 ± 5 7 ± 4 0.984
CD19+,% 21 ± 12 17 ± 7 0.365
Data are presented as mean ± SD, as number (percentage), or as median (interquartile range).
§p <0.05, ※p <0.01.
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groups. (Table 2, Figure 1)
Correlation between plasma cytokines and clinical
manifestation in AIHA
Correlation analyses between plasma cytokine levels and
clinical parameters including hemoglobin level, reticulo-
cyte count, and lactate dehydrogenase were performed
among 37 AIHA patients of both primary and SLE-
related genre (Figure 2). Among the significantly up-
regulated cytokines, CXCL13 was found to be negatively
correlated with hemoglobin level (r = -0.332, p = 0.044),
while positive correlation was found between CCL4 and
reticulocyte count (r = 0.456, p = 0.005).
Discussion
As one of the earliest acknowledged autoimmune disor-
ders, warm antibody AIHA occurs in 1.25-2.6:100,000
persons per year [1,2]. The diagnostic panel of AIHA is
mainly based upon immunohematological methods de-
veloped since mid 20th century. Our understanding of
the pathogenesis of AIHA is still limited except for itshigh prevalence of autoantibody. Fagiolo et al. reported
enhanced IL-10 but decreased IL-12 production among
peripheral blood mononuclear cells from primary AIHA
patients, which indicated IL-12/IL-10 imbalance and
possible Th1/Th2 dysregulation [4]. However, the repeat-
edly observed IL-10 upregulation was later attributed to
regulatory T cells for Th1 inhibition, and the key Th
functional subgroup was argued to be Th1 instead of
Th2 or Th17 [5,6]. In the present study, we found 2.1-
and 2.9-fold elevation of plasma CXCL13, a specific che-
mokine ligand for CXCR5, among primary and SLE-
related AIHA patients, respectively. Meanwhile, plasma
cytokines hallmarked for established Th subgroups in-
cluding IFN-γ, IL-4, and IL-17 were not found elevated
in either AIHA genre. Follicular helper T cell (Tfh) has
recently been acknowledged as an independent Th
population characterized by surface marker CXCR5. Tfh
is crucial for the formation and maintenance of germinal
center, and the defect of Tfh self-tolerance may be re-
sponsible for autoimmune disorders, especially those
marked with high level autoantibody production [8]. We
supposed that Tfh might play an important role in the
Table 2 Plasma cytokine portraits of primary and SLE-related AIHA patients (pg/ml)
Primary (n = 19) SLE-related (n = 18) Health control (n = 10)
IFN-γ 30.93 (19.53-45.66) 36.83 (26.72-69.23) 48.78 (38.10-61.94)
I-309/CCL1 65.26 (38.62-108.86)※ 123.78 (81.56-192.06) 179.66 (96.27-194.22)
MCP-1/CCL2 557.52 (366.62-709.14)※ 683.57 (546.29-1070.0)※ 284.96 (200.73-372.66)
MIP-1α/CCL3 77.23 (64.74-119.83) 114.56 (78.54-162.82) 115.37 (93.05-133.28)
MIP-1β/CCL4 23.73 (12.38-38.30)※ 18.75 (11.11-33.73)※ 5.05 (4.02-10.22)
MIP-1δ/CCL15 (×104) 0.88 (0.72-1.16) 0.55 (0.29-1.05) 1.37 (0.56-1.85)
RANTES/CCL5 (×103) 4.12 (2.40-7.38) 5.89 (1.52-16.33) 5.03 (1.94-7.24)
Eotaxin/CCL11 95.41 (64.34-138.11) 118.44 (91.65-166.06) 120.81 (92.81-133.95)
Eotaxin-2/CCL24 623.34 (329.62-810.59)※ 412.51 (282.29-720.39) 289.56 (206.08-370.20)
MIG/CXCL9 (×103) 2.89 (1.95-5.15) 3.11 (2.02-10.26) 2.36 (1.82-4.12)
BLC/CXCL13 147.90 (104.11-436.02)※ 203.45 (110.74-290.42)※ 69.14 (56.24-100.39)
ICAM-1 (×105) 1.34 (0.66-1.99) 0.60 (0.49-0.93)※ 1.88 (0.95-2.73)
G-CSF 11.29 (4.15-24.12) 16.44 (12.83-22.74) 25.12 (14.47-28.15)
M-CSF 35.48 (19.14-66.10)※ 82.47 (29.22-181.19) # 122.47 (71.49-150.85)
GM-CSF 36.70 (23.65-48.62) 41.60 (25.59-78.01) 48.22 (39.60-72.10)
IL-1α 7.51 (3.00-26.10)※ 27.28 (7.85-60.07)# 42.77 (24.27-53.30)
IL-1β 63.98 (40.83-159.84) 133.24 (89.85-223.31)# 203.08 (98.42-223.41)
IL-1ra 202.27 (121.20-368.22) 416.94 (192.30-563.72) 121.82 (89.31-196.76)
IL-2 9.04 (5.14-12.20) 9.81 (6.83-18.59) 11.12 (9.43-13.68)
IL-4 8.98 (6.04-16.53) 25.87 (8.61-67.04)# 29.64 (13.45-35.24)
IL-5 67.17 (46.65-116.94)※ 104.56 (55.58-155.07) 150.04 (103.54-176.69)
IL-6 52.20 (40.23-76.39) 71.41 (40.80-106.07) 62.45 (52.92-72.92)
IL-6sR (×103) 4.05 (3.49-4.70) 4.31 (3.45-5.17) 4.57 (3.78-4.86)
IL-7 72.16 (44.68-115.49) 85.55 (59.18-147.61) 81.55 (72.15-110.65)
IL-8/CXCL8 8.66 (5.81-26.17)※ 19.15 (9.23-26.68)※ 4.84 (3.95-7.21)
IL-10 26.68 (17.98-42.12) 37.50 (19.68-71.93) 15.22 (14.40-26.26)
IL-11 205.97 (61.19-342.55)※ 324.66 (174.49-546.81)※ 666.37 (487.65-861.28)
IL-12p40 301.15 (83.39-558.00) 570.79 (234.36-1207.2) 277.58 (151.29-403.68)
IL-12p70 4.96 (2.52-9.90)※ 16.41 (4.91-27.76)# 17.04 (10.93-22.00)
IL-13 6.82 (4.40-9.99)※ 10.18 (5.87-14.10) 10.87 (10.53-14.63)
IL-15 149.92 (61.75-478.57) 130.10 (87.61-216.20) 194.64 (169.31-233.75)
IL-16 127.04 (87.19-188.99) 187.65 (105.95-365.92) 168.00 (102.51-214.64)
IL-17 89.62 (36.65-197.82)※ 184.42 (78.67-298.60)※ 438.99 (279.09-667.12)
TIMP-1 (×104) 1.15 (0.87-1.46) 1.63 (0.77-3.29) 2.18 (1.13-3.67)
TIMP-2 (×104) 1.62 (1.37-1.78) 1.97 (1.40-2.56) 1.97 (1.66-2.26)
PDGF-BB (×103) 2.45 (1.79-2.83) 2.39 (1.99-3.00) 1.56 (1.44-2.00)
TNFα 57.42 (31.45-106.25) 85.66 (36.50-121.91) 104.09 (87.59-148.24)
TNFβ 28.24 (26.75-71.80)※ 46.24 (27.84-128.56) 92.78 (64.99-144.54)
sTNFRI (×103) 3.41 (2.63-3.68)※ 4.43 (2.67-5.18)※ 1.21 (0.89-1.72)
sTNFRII (×103) 3.30 (2.12-4.99)※ 6.99 (3.84-11.24)※# 2.05 (1.37-2.70)
Data are presented as median (interquartile range). The level of significance for pairwise comparisons was adjusted when multiple comparisons were performed
(p = 0.05 / 3 = 0.017).
※p <0.017 compared to health control; #p <0.017 compared to primary AIHA.
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Figure 1 Plasma level of CXCL13, CXCL8, CCL2, CCL4, sTNFRI, and sTNFRII in primary AIHA, SLE-related AIHA, and health control
groups. The level of significance for pairwise comparisons was adjusted when multiple comparisons were performed (p = 0.05 / 3 = 0.017).
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Figure 2 Correlation between hemoglobin and plasma CXCL13
level (A), reticulocyte count and plasma CCL4 level (B), among
both primary and SLE-related AIHA patients.
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tients, and CXCL13 could emerge as a potential circulat-
ing marker for disease severity.
CCL2, CCL4, CXCL8, and sTNFRI upregulation repre-
sented common immune aberration in addition to
CXCL13 in both primary and SLE-related AIHA. Inter-
estingly, unlike CXCL13 whose plasma level reflected se-
vere disease, CCL4 might serve as an indicator for
robust bone marrow compensation among AIHA pa-
tients. Known as macrophage inflammatory protein
(MIP)-1β, CCL4 closely interacted with MIP-1α/CCL3
which had been proved to inhibit the proliferation of im-
mature erythroid progenitors [9,10]. Therefore, elevated
level of circulating CCL4 instead of CCL3 among AIHA
patients might indicate a boost in their erythroid prolif-
eration and reticulocytosis. On the other hand, CCL2
and CXCL8, both capable of inducing respiratory burst
as well as being chemoattractants, had been under inten-
sive investigation among SLE patients [11-18]. Although
both cytokines were argued to be elevated in the sce-
nario of SLE, CCL2 was regarded as an important bio-
marker for lupus nephritis flair [13-16], and CXCL8 for
lupus associated interstitial lung diseases [17,18]. In
immune-mediated hemolytic anemia canine models,CCL2 was also argued to experience marked up-
regulation and to demonstrate prognostic value [19].
The most intriguing finding of the present study was
the subtly different patterns of soluble TNFR between
primary and SLE-related AIHA patients. Human TNFRII
expressed restrictively upon certain T cell populations
and a few other cell types, while TNFRI was found on al-
most all cell types. The binding of TNF to these two
types of receptors generated completely opposite cell
fates, with signaling via TNFRI favoring apoptosis and
TNFRII survival [20,21]. Various defects in the TNFRII
pathway, including upregulated expression of TNFRII
and TNFRII shedding, had been implicated in SLE pa-
tients [22,23]. Based upon the 3.4-fold increase in
plasma sTNFRII level, our data supported the hypothesis
of TNFRII pathway defect in SLE-related but not pri-
mary AIHA. The reason for the elevation of plasma
sTNFRI in both AIHA groups was still unclear, since
neither TNFR type was expressed on erythrocytes [20].
From the clinical aspect of view, differential diagnosis
between primary and secondary AIHA is often challen-
ging, especially among those with positive antinuclear
antibody. Aside from younger age and slight female gen-
der preference, SLE-related AIHA seemed to demon-
strate less prominent erythrocyte destruction as
indicated by serum bilirubin and LDH levels, which
could be attributed to impaired scavenging function of
reticulo-endothelial system previously described in SLE
[24]. Instead of hypocomplementemia which was trad-
itionally believed to be an important diagnostic clue of
SLE, the presence of anticardiolipin antibody and up-
regulation of plasma sTNFRII might be of greater diag-
nostic value for SLE-related AIHA.
The present study should be viewed in the light of its
limitations. It is usually hard to give an exact signifi-
cance to lab findings concerning clinical situations of
high heterogeneity such as SLE. Both disease activity
and precedent therapeutic methods could strongly influ-
ence lab findings. The study population was relatively
small due to low incidence rate of AIHA. The descrip-
tive nature of the present study withheld affirmative
causal deduction, and further functional studies could
help to clarify the detailed mechanism of specific cyto-
kine induced signaling in AIHA.
Conclusions
The timely differential diagnosis between primary and
SLE-related AIHA often looms as practical challenge
under clinical scenario, given the key underlying im-
mune aberration of AIHA remains unclear. The present
study performed circulating inflammatory cytokine pro-
filing among primary and SLE-related AIHA patients
and revealed novel cytokine patterns in the pathogenesis
of AIHA as well as parameters for clinical identification
Wu et al. Journal of Translational Medicine  (2015) 13:112 Page 7 of 7of SLE-related patients. Plasma CXCL13 and CCL4
could act as circulating biomarkers in AIHA, and indi-
cated disease severity and erythroid compensation, re-
spectively. Detection of anticardiolipin antibody and
higher levels of plasma sTNFRII might favor the diagno-
sis of SLE-related instead of primary AIHA.
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